There are millions of people suffering from acquired hyperpigmentation diseases such as melasma all over the world. The appearance of melasma is indicated by symmetrical, hyperpigmented patches and macules that can take on several forms, such as blotchy, irregular, arcuate, and polycyclic. Hormonal treatments (including oral contraceptives), pregnancy, antiepileptic drugs, intense sun exposure, phototoxic substances, and genetic predisposition are common triggers of melasma. There are several treatments available for patients who are suffering from melasma. Typically, first-line treatments include medications that influence the route where pigment is produced, broad-spectrum photoprotection, and camouflage. Chemical peels are frequently included in second-line treatment, albeit patients with darker skin should use caution while using them. While carrying a high risk of making the disease worse, laser and light therapy are potentially viable options for people who have failed previous treatments. There is a need for an alternative strategy with fewer side effects and high success rates because of several shortcomings and consequences of existing treatments. Novel approaches, including microemulsions, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers, liposomes, niosomes, transfersomes, aquasomes, ethosomes, penetration enhancer vesicles, chitosan nanoparticles, ethyl cellulose nanoparticle, and fullerene, lead to greater effectiveness, quicker recovery, and higher patient satisfaction.This review summarizes the novel approaches and clinical trials used for the management of melasma.